Document is current
Any future updates will be listed below
-
Authors
Donald, Peter R.
Kaufmann, Stefan H.E.
Schaub, Dagmar
Thee, Stephanie
Lange, Christoph
-
Funding
Funding for this research was provided by:
Stellenbosch University
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 24 July 2024
First Online: 2 August 2024
Declarations
:
: SK declares honoraria from LTS Lohmann Therapie-Systeme AG, Germany and Charité Cluster Advisory Board. He is coinventor of two patents: for the TB vaccine VPM1002 and for a biosignature for TB prognosis.The TB vaccine VPM1002 is licensed to Serum Life Science Europe GmbH (former Vakzine Projekt Management), Hannover, Germany and sublicensed to Serum Institute of India PVT. Ltd., Pune, India. The vaccine is currently undergoing phase III efficacy trial testing. SK is also coholder of a patent licensed to Serum Institute of India PVT. Ltd., Pune, India.SK is coinventor and coholder of a patent of a biosignature for TB prognosis.ST declares payments for lectures/ presentations/ manuscript writing from Vertex Pharmaceutical, Viatris and PARI GmbH. She has an unpaid leadership/ fiduciary role in ERS crc AMR Lung.CL is supported by the German Center of Infection Research (DZIF). Outside of the scope of this work CL provided consultation service to INSMED (producer of liposomal amikacin as an inhalative suspension for the treatment of NTM-PD) and received speakers honoraria from INSMED, GILEAD, Astra Zeneca and GSK. Outside of the scope of this work CL is a member of the Data Safety Board of trials from Medicines sans Frontiers.PD and DS declare no competing interests.
